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Running title: Crystal structure of human histamine H1 receptor 
Summary 
Histamine H1 receptor (H1R) antagonists (H1R-antagonists) are very effective drugs inhibiting the H1R 
action and alleviating the symptoms of allergic reactions. The crystal structure of H1R-T4 lysozyme fusion- 
protein in complex with doxepin, a first-generation H1R-antagonist, allows us to characterize its 
ligand-binding pocket in detail. Doxepin sits much deeper in the pocket than the antagonists in other 
aminergenic G protein coupled receptor (GPCR) structures and directly interacts with the highly conserved 
Trp4286.48, a key residue in GPCR activation. This well-conserved pocket and its mostly hydrophobic nature 
contribute to low selectivity of doxepin and other first-generation compounds causing considerable 
side-reactions.  The pocket is associated with an anion-binding region occupied by a phosphate molecule. 
Docking of various second-generation H1R-antagonists reveals that the unique carboxyl-group present in 
this class of compounds interacts with Lys1915.39 and/or Lys179ECL2, both of which form part of the 
anion-binding region and are not conserved in other aminergenic receptors.
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Histamine is a biogenic amine and an important mediator in various physiological and pathophysiological 
conditions such as gastric acid secretion, arousal state, locomotor activity, feeding, drinking, allergy and 
inflammation1,2,3.  Histamine exerts its effects through the activation of four distinct histamine receptors 
(H1, H2, H3 and H4) that belong to the G protein-coupled receptor (GPCR) superfamily.  Histamine H1 
receptor (H1R), was originally cloned from bovine adrenal medulla by Yamashita et al. in 19924, is now 
known to be expressed in various tissues including airway, retina, intestinal and vascular smooth muscle, 
brain, and lymphocytes2. In type I hypersensitivity allergic reactions, H1R is activated by histamine released 
from mast cells, which are stimulated by various antigens5. Many studies have been performed to develop 
H1R-antagonists, also known generally as antihistamines. Many of these compounds have inverse agonism 
activity and inhibit the action of histamine on H1R to alleviate the symptoms of the allergic reactions, 
making H1R one of the most validated drug targets judging from the number of drugs approved6. H1R 
displays constitutive activity, and H1R-antagonists generally act as inverse agonists for H1R7,8. Development 
of H1R-antagonists has progressed through two generations. First-generation drugs such as pyrilamine and 
doxepin (known under many brand-names such as SinequanTM and AdapinTM, Supplementary Fig. 1) are 
effective H1R-antagonists.  These compounds are, however, known to show considerable side effects such 
as sedation and appetite increment, dry mouth, hypertension, tachycardia and arrhythmia, because of 
penetration across the blood-brain barrier (BBB), and low receptor selectivity.  These H1R-antagonists can 
bind not only to H1R but also to other aminergic GPCRs, monoamine transporters and cardiac ion channels. 
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Second-generation drugs such as cetirizine, terfenadine and olopatadine (Supplementary Figure 1) are less 
sedating and in general have fewer side effects.  The improved pharmacology of the second-generation 
zwitterionic drugs can be attributed to a new carboxylic moiety, in combination with the protonated-amine, 
which significantly reduces brain permeability, although residual CNS effects are still reported9. The 
introduction of the carboxyl moiety also improves the H1R selectivity of these compounds, but certain 
second-generation H1R antagonists, such as terfenadine and astemizole, sill show cardiotoxicity because of 
the interaction with cardiac potassium channels10,11. Therefore, structural details of the H1R agonist binding- 
pocket will be highly beneficial for guiding rational design of new H1R antagonists that do not penetrate the 
BBB while maintaining H1R selectivity.  
A first-generation H1R-antagonist, doxepin, can cause many types of side effects due to its 
antagonistic effects on H2R12, serotonin 5-HT2, α1-adrenergic, and muscarinic acetylcholine receptors13 in 
addition to the inhibition of the reuptake of serotonin and norepinephrine14 . Although GPCR homology 
models have been successfully used for the design and discovery of novel GPCR ligands (for reviews, see 
refs 15 and 16), reliable receptor structures are essential to understand ligand selectivity at the molecular 
level. Recently determined GPCR structures have enabled structure-based approaches to modeling ligand 
interactions in the binding pocket17,18,19,20,21,22,23 and are already yielding novel chemotypes predicted by 
virtual screening of large chemical libraries24,25. Here, we report the 3.1 Å resolution structure of the H1R-T4 
lysozyme fusion protein (H1R-T4L) complex with doxepin. The crystal structure reveals the atomic details 
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of doxepin binding and its inverse agonistic activity. The H1R crystal structure and the models of 
second-generation H1R antagonists will be highly beneficial for guiding rational design of ligands that do 
not penetrate the BBB while maintaining H1 selectivity. For example, one can use the H1R structure to 
design optimally bound carboxyl substitutes for other existing first-generation H1R antagonists. It can also 
guide further medicinal chemistry efforts for optimal replacement of the carboxyl group by other 
determinants of low BBB permeability. 
 
Overall architecture of H1R  
H1R constructs were screened for expression and stability as green fluorescent protein (GFP) fusions in 
Saccharomyces cerevisiae26.  The most stable construct was expressed in Pichia pastoris, purified in 
detergent solution and crystallized in lipidic cubic phase supplemented with cholesterol.  In the H1R 
construct, we replaced most of the third cytoplasmic loop (ICL3) (Gln222-Gly404) with T4-lysozyme27  
and truncated the N-terminal 19 residues (Met1-Lys19). H1R-T4L showed similar binding affinities for 
H1R-antagonists and for histamine as the wild type H1R expressed in yeast cells (Supplementary Table 1) 
and in COS-7 cells28. The structure of H1R-T4L was determined in complex with the H1R-antagonist 
doxepin at 3.1 Å resolution (Supplementary Table 2).  
 The main fold of the H1R consists of the canonical 7 transmembrane bundle of α-helices (Fig. 
1a), which is structurally most similar to the aminergic receptors: β2-adrenergic (β2AR)18, β1-adrenergic 
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(β1AR)19 and dopamine D3 (D3R)23 receptors, while having larger deviations from the more 
phylogenetically distant rhodopsin17,21, A2A adenosine receptor (A2AAR)20 and CXCR422 (Supplementary 
Table 3). H1R also shares the common motifs with other GPCRs including D(E)RY in helix III, CWxP in 
helix VI and NPxxY in helix VII, as well as a disulfide bond connecting extracellular loop 2 (ECL2) with 
the extracellular end of helix III (Cys1003.25 to Cys180).  Like most other GPCR structures, H1R also has a 
short amphiphilic α-helix (helix VIII) following helix VII, although H1R lacks the palmitoylation site at the 
end of helix VIII found in many other GPCRs29.  
 Previous GPCR structures revealed that not only the residues in the transmembrane segments 
but also those in the loops are critical for ligand specificity17,18,19,20,21,22,23.  ECL2 connecting helices IV and 
V is attached to helix III through a disulfide bond between Cys180 in ECL2 and Cys1003.25 in helix III.  
Seven residues (Phe168-Val174) before the disulfide are not included in the structure as they did not have 
interpretable densities. A section of ECL2, between the disulfide bridge and the extracellular end of helix V, 
is particularly important because it is located at the entrance to the ligand-binding pocket. This section of 
ECL2 contains 7 amino acids in H1R, as compared to 5 in β2AR , 4 in D3R, and 8 in A2AAR. The extra 
length of this ECL2 section is apparently accommodated by the increased distance between the extracellular 
ends of helices III and V by ~1.5 Å and ~3.1 Å when compared to β2AR and D3R, respectively (Fig. 1b,c).  
This creates more space within the ligand-binding pocket, which can now accommodate the larger 
second-generation H1R-antagonists as discussed below.   
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Some unique features are also observed in the transmembrane segments. A conserved 
Pro1614.59 induced kink in helix IV forms a tight i-3 helical turn instead of i-4 as in β2AR and D3R (Fig. 2a).  
This tighter turn allows accommodation of a bulky Trp side chain at position 4.56, which seems essential for 
ligand specificity of aminergenic GPCRs because this position is occupied by Ser in β2AR and D3R, and 
the mutations of this Trp in the guinea pig H1R to Ala, Met and Phe reduce the affinity against the antagonist 
pyrilamine30. 
  The "ionic lock", a salt bridge between Arg3.50 in the conserved D(E)R3.50Y motif and 
Asp/Glu6.30, which is suggested to stabilize the inactive conformation, was observed in rhodopsin 
structures17,21 and dopamine D3R23, but broken in all the other GPCRs18,19,20,22. In H1R, Arg1253.50 of the 
D(E)R3.50Y motif does not form a salt bridge either with Glu4106.30 or with Asp1243.49. Instead, the side 
chain of Arg1253.50 adopts in a new conformer relative to previous structures forming a hydrogen bond to 
Gln4166.36 in helix VI (Fig. 2b). Different structures of the “ionic lock” regions of the receptors could be 
caused by modifications of ICL3. Otherwise it might be related to the different levels of constitutive 
activities of the receptors. 
 
Doxepin isomers and conformers 
 The H1R structure was determined with an H1R-antagonist doxepin (Supplementary Fig. 1) that shows 
very high affinity for H1R (Ki = 2.3-2.4 nM, Supplementary Table 1) as well as for several other aminergic 
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receptors12,13. The doxepin used in this study contains a mixture of E- and Z- isomers, and each isomer can 
take two distinct rotational conformers of the dibenzo[b,e]oxepin ring, resulting in 4 distinct conformers 
(conformers 1 to 4, Supplementary Fig. 2). Two conformers, one E-isomer (conformer 1) and one Z-isomer 
(conformer 4) fit the electron density better than the other two (Supplementary Fig. 3). This result is also 
consistent with the Rfree and the averaged B-factor values for each conformer (Supplementary Table 5). We 
used the 1:1 mixtures of the E- and the Z- isomers in the refinement. The two conformers are 
indistinguishable at this resolution and have nearly identical interactions with the binding pocket, so in the 
following sections we will refer to the E-isomer unless noted otherwise.  
 
Ligand binding pocket 
Doxepin binds in a pocket mainly defined by the side chains of helices III, V and VI (Fig. 3a,b). Asp1073.32, 
a strictly conserved residue in aminergic receptors (Supplementary Table 4), and forms an anchor salt bridge 
with the amine moiety of the ligand. This interaction has been reported to be essential for the binding of 
H1R-antagonists as well as agonists by the mutational studies31,32,33. This amine moiety is connected via a 
flexible carbon chain to the tricyclic dibenzo[b,e]oxepin ring in a hydrophobic pocket comprised of the side 
chains of helices III, V and VI. The tricyclic ring of doxepin sits much deeper (by ~5 Å) in the binding 
pocket than the ligands in the other non-rhodopsin GPCR structures (Fig. 3c). The ligand is surrounded 
mainly by highly conserved residues among aminergenic receptors including Ile1153.40, Trp4286.48, 
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Phe4246.44 and Phe4326.52, whereas the non-conserved residues Trp1584.56 and Asn1985.46 in the pocket make 
only minor hydrophobic interactions with doxepin (Fig. 3a,b). The importance of a large side chain at 
position 6.52 has been suggested for the binding of pyrilamine.30,33. Thr1123.37 can form a hydrogen bond to 
the oxygen atom of the E-isomer (but not the Z- isomer) of doxepin as shown in Fig. 3a,b. A suboptimal 
geometry and bifurcated nature of this H-bond suggest that it does not contribute significantly to binding 
affinity. This observation is also consistent with binding of the isomer-specific doxepin analogue 
olopatadine, as described below. This well-conserved pocket and its mostly hydrophobic nature should 
contribute to low selectivity of doxepin and other first-generation H1R-antagonists13,32.  Moreover, because 
of its deep binding position, doxepin does not interact with ECL2, whose highly variable primary and 
tertiary structures are known to contribute to binding specificity of GPCR ligands34.  
A novel feature of the H1R-doxepin complex is the existence of an anion-binding site at the 
entrance to the ligand-binding pocket (Fig. 3d). A phosphate ion, which is present at a high concentration in 
the crystallization buffer (300mM ammonium phosphate), is modeled into the observed strong density in 
the site.  This model is supported by the fact that PO43- affects the binding of some ligands and the stability 
of H1R (Supplementary Tables 1 and 6). The phosphate ion is coordinated by Lys179 in ECL2, Lys1915.39, 
Tyr4316.51 and His4507.35; all of which, except for Tyr4316.51 are unique to H1R (Supplementary Table 4).  
This encasement of the ligand in the pocket combined with an ionic interaction between the phosphate ion 
and the tertiary amine of doxepin (N-O distance 4.8 Å) suggest that PO43- may serve as a positive modulator 
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of ligand-binding. This hypothesis has been validated by comparing thermostability (Supplementary Table 
4) and ligand affinity (Supplementary Table 1) in buffers with and without PO43- .  Thermostability of the 
receptor is increased in the presence of phosphate for all ligands except for cetirizine, which likely prevents 
the phosphate-binding according to the modeling study as discussed below. The phosphate effect is 
observed at a phosphate concentration as low as 1.5 mM suggesting its physiological relevance. The affinity 
of histamine and pyrilamine to the receptors also increased in the presence of phosphate.   
 
H1 selectivity of the second-generation H1R-antagonists 
Supplementary Figure 1 lists the first- and second-generations of H1R-antagonists. It has been shown that 
the second-generation H1R-antagonists are much more specific to H1R and show much lower affinity to the 
other aminergenic receptors32,35. H1R-antagonist specificity has been previously analyzed using H1R 
homology models based on the bacteriorhodopsin structures in combination with the H1R antagonist 
pharmacophore model and mutational studies (for example, refs 30, 36 and 37).  These studies have 
successfully determined some residues important for the selectivity including Lys1915.39, however, 
contributions of the ECL residues have not been examined because these loops could not be modeled 
accurately based on the bacteriorhodopsin structure. Our H1R X-ray structure with the ECL loops should 
significantly improve the understanding of the H1R-antagonist selectivity.  Using flexible ligand-receptor 
docking38,39 in the ICM molecular modeling package40 (see also Methods), we have studied the H1R 
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selectivity for representative second-generation zwitterionic H1R-antagonists: olopatadine, acrivastine, 
R-cetirizine (levocetirizine, XyzalTM) and fexofenadine (AllegraTM) (Fig. 4).  Olopatadine (Fig. 4a) is a 
close doxepin analogue with a methyl-carboxyl substitution in one of its benzene rings.  Its binding mode 
closely resembles doxepin, while the carboxyl group extends out of the pocket toward the extracellular 
space and interacts with Lys1915.39 and Tyr1083.33 without displacing the phosphate ion. These additional 
interactions can explain a reduced effect of the mutation of the conserved Asp1073.32 to Ala on olopatadine 
binding (14 fold for olopatadine as compared to 280 fold for doxepin) 32,41. The orientation of the carboxyl 
moiety in the ECL region dictates that the oxygen atom of the oxepin ring is in a position where it cannot 
form a H-bond with Thr1123.37. Although the marketed drug is only the Z-isomer, both olopatadine Z- and 
E-isomers show similar H1R affinities41, which is also in line with our docking results for the E-isomer (not 
shown). 
Acrivastin (Fig. 4b) has a different chemical scaffold with a carboxyl group in its pyridine ring.  
Its longer carbon chain positions the carboxyl group higher in the ECL region, where it can form salt bridges 
to both Lys1915.39 and Lys179 (ECL2) amine moieties. R-cetirizine (Fig. 4c) has its carboxylic moiety 
attached directly to a piperazine amino group. The conformational modeling suggests that the carboxyl 
moiety can reach towards the ECL region forming salt bridges to Lys1915.39 and to Lys179. Finally, 
fexofenadine (R-isomer, Fig. 4d) has the most extended carboxyl-containing substituent, which reaches 
outside of the binding cavity and forms a salt bridge to Lys1915.39.  
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Modeling of the second-generation H1R-antagonist binding to H1R suggests that no significant 
protein backbone rearrangements are required to accommodate these diverse ligands. Instead, the enhanced 
H1R selectivity of these compounds32,35 can be explained by the specific interaction of the carboxyl group 
with Lys residues in the ECL region, unique to H1R. The result also shows a good agreement with earlier 
modeling and site-directed mutagenesis studies. Lys1915.39 is known to be important for increasing affinity 
for some of these ligands30,42,43, whereas the involvement of Lys179 was suggested in the modeling study of 
8R-lisuride into the ligand-binding pocket 44.  Our modeling results also suggest that olopatadine is the 
only second-generation compound studied here for which the carboxyl moiety does not interfere with 
phosphate binding. The results are also supported by the fact that the presence of the phosphate ion 
increased the thermal stability of the H1R-doxepin or H1R-olopatadine complex, whereas it does not affect 
the stability of the H1R-cetirizine complex (Supplementary Table 6). 
 
Stabilizing inactive H1R conformation by H1R-antagonists 
H1R-antagonists act as highly effective inverse agonists of H1R, which reduce basal activity of the receptor 
and therefore are expected to interfere with the key molecular switches involved in the GPCR activation 
mechanism. One of the switches is represented by Trp6.48 of the conserved CWxP6.50 motif, which helps to 
stabilize rhodopsin in its inactive dark state through a direct interaction with retinal. The recently published 
structure of the active-state A2AAR45 also showed that Trp6.48 participates in the activation-related 
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conformational changes, where a small ligand induced shift of Trp6.48 was observed in concert with the large 
movement of the intracellular part of helix VI. In other receptors, the role of Trp6.48 is less obvious, e.g. it 
lacks direct ligand interactions with either inverse agonists or full agonists of β2AR46.  It is interesting to 
note that in the H1R structure, like in inactive rhodopsin, the H1R-antagonist doxepin does make extensive 
hydrophobic interactions with the Trp4286.48 rings, which is unique among the known non-rhodopsin GPCR 
structures and could stabilize the hydrophobic packing around helix VI (Fig. 3c). Another important 
ligand–induced switch described in β2AR is activation-related contraction of the extracellular ligand-binding 
pocket36. Because the natural agonist histamine is much smaller than bulky H1R-antagonists, some 
contraction of the binding pocket is likely to accompany ligand induced H1R activation. Bulky compounds, 
capable of blocking both activation-related contraction of the pocket and the Trp4286.48 switch would be 
very efficient in locking H1R in an inactive conformation, which is likely to explain as much as 78% 
reduction of H1R basal activity by some H1R-antagonists 8. 
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Methods summary 
    H1R-T4L was expressed in yeast Pichia pastoris. Ligand binding assays were performed as described 
in Methods. Pichia pastoris membranes were solubilized using 1% (w/v) n-dodecyl-β-D-maltopyranoside 
and 0.2% (w/v) cholesteryl hemisuccinate, and purified by immobilized metal ion affinity chromatography 
(IMAC). After IMAC, the C-terminal GFP was cleaved by Tobacco Etch virus (TEV) protease. Then the 
sample mixture was passed through IMAC to remove the cleaved His-tagged GFP and TEV protease. 
Receptor crystallization was performed by lipidic cubic phase (LCP) method. The protein-LCP mixture 
contained 40% (w/w) receptor solution, 54% (w/w) monoolein, and 6% (w/w) cholesterol. Crystals were 
grown in 40-50 nl protein-laden LCP boluses overlaid by 0.8 μl of precipitant solution (26-30% (v/v) 
PEG400, 300 mM ammonium phosphate, 10 mM MgCl2, 100 mM Na-citrate pH 4.5 and 1 mM doxepin) 
at 20 °C. Crystals were harvested directly from LCP matrix and flash frozen in liquid nitrogen. X-ray 
diffraction data were collected at 100 K with a beam size of 10 x 10 microns on the microfocus beamline 
I24 at the Diamond Light Source (UK). Data collection, processing, structure solution and refinement are 
described in Methods. 
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Figure legends  
Fig. 1. Structure of H1R complex with doxepin.  (a) Ribbon representation of the H1R structure.  
Doxepin is shown as yellow spheres whereas the phosphate ion as spheres with carbon, and oxygen atoms 
colored orange and red, respectively. Disulfide bonds are shown as yellow sticks and Trp428 and Asp107 as 
pink sticks. Three conserved motifs D(E)R3.50Y, CWxP6.50 and NP7.50xxY are highlighted in blue. (b) 
Superimposition of the H1R (green) and β2AR (cyan) structures. (c) Same as (b) but with the D3R structure 
colored magenta.  
 
Fig. 2. Comparison of the structures of H1R, β2AR and D3R. (a) Variations in backbone structures of 
the helix IV proline-induced kink (H1R: green, β2AR: cyan, D3R: magenta). The side chain of Trp1584.56 
and Pro1614.59 of H1R and the equivalent residues of β2AR (Ser1654.57 and Pro1684.60) and of D3R 
(Ser1654.57 and Pro1674.59) are also shown. (b) Variations in the D(E)RY motif structures of H1R, β2AR and 
D3R colored in green, cyan and magenta, respectively. Side chains of Asp1243.49, Arg1253.50, Glu4106.30 of 
H1R and the equivalents of β2AR and D3R are represented as stick models. For H1R, Gln4166.36, which 
forms a hydrogen bond with Arg1253.50 , are also shown. Possible hydrogen bonds are indicated by dotted 
lines.  
 
Fig. 3. Binding interactions of doxepin. (a) Doxepin in the ligand binding pocket is shown as sticks with 
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cyan carbon atoms, whereas the contact residues within 4 Å of doxepin are shown as sticks with grey 
carbon atoms. Nitrogen and oxygen atoms are colored blue and red, respectively. An E-doxepin isomer is 
used for all the figures. Possible hydrogen bonds/salt bridges are indicated by dashed lines. (b) Schematic 
representation of doxepin binding interactions, shown as blue dotted lines for the salt bridges/hydrogen 
bonds and black for hydrophobic interactions. (c) Ligand binding positions in the structures of 
non-rhodopsin GPCRs. Carbon atoms of doxepin (H1R) are shown in grey, carazolol (β2AR) in cyan, 
eticlopride (D3R) in magenta and ZM241385 (A2AAR) in grey. Doxepin occupies the deepest position 
among them and directly interacts with Trp4286.48 in the conserved CWxP motif. (d) Structure of the 
anion-binding region at the entrance of the ligand-binding pocket. A phosphate ion was modeled into the 
observed electron density in the region. Nitrogen and oxygen atoms are colored blue and red, respectively. 
Possible hydrogen bonds/salt bridges are indicated as blue dotted lines.  
 
Fig.4 Interactions of second-generation selective H1R-antagonists with the H1R ligand-binding pocket.  
Conformation of each complex was predicted by global optimization of the ligand in the all-atom flexible 
H1R model 38,39,40 based on the structure of H1R-doxepin complex. Carbon atoms for (a) Z-olopatadine 
co-bound with PO43- ion, (b) acrivastine, (c) R-cetirizine (levocetirizine), and (d) fexofenadine are colored 
magenta. Nitrogen and oxygen atoms are colored blue and red, respectively. Ligand contact residues of H1R 
are shown with grey carbon atoms; parts of helices III, IV and ECL2 are not displayed for clarity. Hydrogen 
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bonds between ligands and contact side chains are shown in cyan. These figures were prepared with ICM 
molecular modeling package (Molsoft LLC). 
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Construction of the H1R expression vectors for Pichia pastoris 
The coding sequence of the full-length human histamine H1 receptor (H1R-fl), in 
which N-linked glycosylation sites (Asn5 and Asn18) were mutated to glutamines, was 
synthesized with optimization of codon usage for P. pastoris (TAKARA bio Inc.), and cloned 
into the pPIC9K expression vector (Invitrogen). The H1R-T4L construct with N-terminal 19 
residues deletion and insertion of cystein-less (C54T, C97A) T4 lysozyme into the third 
intracellular loop was generated by yeast homologous recombination technique in 
Saccharomyces cerevisiae with the SmaI linearized plasmid pDDGFP2 1 and three PCR 
products with ~30 bp overlapped sequences. The three fragments were individually generated 
by standard PCR techniques with the indicated primers. The generated plasmid integrating 
H1R-T4L followed by TEV cleavage sequence (ENLYFQG), yeast enhanced GFP and 
octa-histidine tag (H1R-T4L-GFP) was isolated from S. cerevisiae. Coding regions of the 
H1R-T4L-GFP fusions were amplified by PCR using a forward primer containing a BamHI 
site (5’-CTA GAA CTA GTG GAT CCA CCA TG-3’) and a reverse primer containing an 
EcoRI site (5’-GCT TGA TAT CGA ATT CCT GCA GTT AAT G-3’). The PCR products 
were digested with BamHI and EcoRI, and subcloned into the pPIC9K vector. 
 
Expression and membrane preparation 
The PmeI linearized pPIC9K expression vector integrating H1R-fl-GFP or 
H1R-T4L-GFP was then transformed into the P. pastoris SMD1163 strain by electroporation 
(2000 V, 25 mF, and 600 Ω) using a Gene Pulser I (Bio-Rad). Clone selection was 
performed on the YPD-agar plate containing 0.1 mg/ml geneticine. A single colony of P. 
pastoris transformant was inoculated into BMGY medium [1% (w/v) yeast extract, 2% (w/v) 
peptone, 1.34% (w/v) yeast nitrogen base without amino acids, 0.00004% (w/v) biotin, 1% 
(w/v) glycerol, 0.1 M phosphate buffer at pH 6.0] at 30 ºC with shaking at 250 rpm until an 
OD600 of 2–6 was reached. The cells were harvested by centrifugation. To induce expression, 
the cell pellet was resuspended to an OD600 of 1.0 in BMMY medium [1% (w/v) yeast extract, 
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2% (w/v) peptone, 1.34% (w/v) yeast nitrogen base without amino acids, 0.00004% (w/v) 
biotin, 0.5% (v/v) methanol, 0.1 M phosphate buffer at pH 7.0] containing 2.5% (v/v) DMSO 
at 30 ºC. Cells were harvested within 20 to 24 hours after induction, and stored at -80 °C. 
Yeast cells were disrupted with 0.5 mm glass beads in a buffer containing 50 mM HEPES, pH 
7.5, 120 mM NaCl, 5%(v/v) glycerol, 2 mM EDTA and EDTA-free protein inhibitor cocktail 
(Roche). Undisrupted cells and cell debris were separated by centrifugation at 3000 x g, and 
yeast membrane were collected by ultracentrifugation at 100,000 x g for 30 min at 4 ºC. 
Washing of the membranes was performed by repeating dounce homogenation and 
centrifugation in a high salt buffer containing 10 mM HEPES, pH 7.5, 1 M NaCl, 10 mM 
MgCl2, 20 mM KCl and EDTA-free protease inhibitor cocktail. Prepared membranes were 
resuspended in a buffer containing 50 mM HEPES pH 7.5, 120 mM NaCl, 20% (v/v) glycerol 
and EDTA-free protease inhibitor cocktail, and snap-frozen in liquid nitrogen and stored at 
-80 ºC until use. Membrane proteins were quantified using the bicinchoninic acid method 
(Pierce). 
 
Purification of H1R-T4L 
Membrane suspension containing H1R-T4L-GFP was thawed and incubated on ice 
for 30 min in the presence of 5 mM doxepin, 10 mg/ml iodoacetamide, and EDTA-free 
protease inhibitor cocktail (Roche). The membrane suspension was poured into the buffer 
containing 20 mM HEPES pH 7.5, 500 mM NaCl, 1% (w/v) n-dodecyl-β-D-maltopyranoside 
(DDM, Anatrace), 0.2% (w/v) cholesteryl hemisuccinate (CHS, Sigma), 20% (v/v) glycerol 
and 2-3 mg/ml membrane, and stirred gently at 4 °C for 1-2 hours. The unsolubilized material 
was separated by centrifugation at 100,000 × g for 30 min. The supernatant was incubated 
with TALON IMAC resin (Clontech) overnight. The resin was washed with twenty column 
volumes of 20 mM HEPES pH7.5, 500 mM NaCl, 10% glycerol, 0.025% (w/v) DDM, 
0.005% (w/v) CHS, 100 µM doxepin and 20 mM imidazole. The protein was eluted with 4 
column volumes of 20 mM HEPES pH 7.5, 500 mM NaCl, 10% glycerol, 0.025% (w/v) 
DDM, 0.005% (w/v) CHS, 500 µM doxepin and 200 mM imidazole. The eluted fractions 
were concentrated to 2.5 ml with a 100 kDa molecular weight cut-off AmiconUltra 
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(Millipore). Imidazole was removed using PD-10 column (GE healthcare). Then the protein 
was loaded onto the Ni-Sepharose high performance resin (GE healthcare) (1.5 ml resin for 
~10 mg of protein). The resin was washed with 20 column volume of 20 mM HEPES pH 7.5, 
500 mM NaCl, 10% glycerol, 0.025% (w/v) DDM, 0.005% (w/v) CHS, 500 µM doxepin and 
20 mM imidazole. The sample was eluted with three column volumes of 20 mM HEPES pH 
7.5, 500 mM NaCl, 10% glycerol, 0.025% (w/v) DDM, 0.005% (w/v) CHS, 1 mM doxepin 
and 500 mM imidazole. Imidazole was removed using PD-10 column (GE healthcare). The 
protein was processed overnight with His-tagged TEV protease (expressed and purified in 
house). TEV protease and the cleaved His-tagged GFP were removed by passing the sample 
through the Ni-Sepharose high performance resin. The receptor was concentrated to 30-40 
mg/ml with a 100 kDa molecular weight cut-off Vivaspin concentrator (Vivascience). Protein 
purity and monodispersity were tested by SDS-PAGE and by size-exclusion chromatography 
using Superdex 200 (GE healthcare). 
 
Lipidic cubic phase crystallization 
    Lipidic cubic phase (LCP) crystallization trials were performed using an in meso 
crystallization robot as previously described 2. 96-well glass sandwich plates were filled with 
40-50 nl protein-laden LCP boluses overlaid by 0.8 µl of precipitant solution in each well and 
sealed with a glass cover-slip. The protein-LCP mixture contained 40% (w/w) receptor 
solution, 54% (w/w) monoolein, and 6% (w/w) cholesterol. Crystallization set-ups were 
performed at room temperature (20-22 °C). Plates were incubated and imaged at 20 °C using 
an automated incubator/imager (RockImager 1000, Formulatrix). Crystals were obtained in 
26-30% (v/v) PEG400, 300 mM ammonium phosphate, 10mM MgCl2, 100 mM Na-citrate pH 
4.5 and 1 mM doxepin (Sigma) (Supplementary Figure 5). Crystals were harvested directly 
from LCP matrix using MiTeGen micromounts and were flash-frozen in liquid nitrogen 
without additional cryoprotectant. 
 
Data collection and refinement 
 X-ray diffraction data were collected at 100 K with a wavelength of 0.97780 Å and with a 
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beamsize of 10 x 10 microns on the microfocus beamline I24 at the Diamond Light Source 
(UK) with a Pilatus 6M detector. Each loop was subjected to a grid scanning 3 in order to 
locate the crystals, which are invisible in the lipidic cubic phase once they are mounted. The 
exact locations and dimensions of the chosen crystals were determined by further grid 
scanning with a smaller search area.  Data collection was carried out by collecting several 
overlapping wedges of data from adjacent positions within a single crystal. The data were 
processed initially with xia2 4 using Mosflm 5 and Scala 6 with the merging statistics used to 
determine an optimum subset of measurements to merge. The final data set consisted of data 
from five of the eight positions recorded, giving a total of 75 degrees of data. These data were 
then remerged with Scala to give the final data set summarized in Table S2. The space group 
was determined to be I422 with one molecule in the asymmetric unit. Diffraction data were 
slightly anisotropic, extending to 2.9 Å in the c* direction and 3.1 Å in the a* and b* 
directions. The structure factors up to 3.1 Å resolution were anisotropically scaled by 
PHASER 7 and then used for the subsequent molecular replacement and refinement. The 
structure was determined by molecular replacement with the program PHASER 7 using two 
independent search models (polyalanine of the 7 TM α-helices, and T4L) from β2AR (PDB 
ID: 2RH1) structure. We chose β2AR as a model structure because it has the highest 
homology of transmembrane helices with H1R (41.7%) among the human GPCR structures. 
For the initial map calculation after molecular replacement, however, we used a β2AR model 
without side chains, loops, ligand, lipids and any solvents, therefore the final H1R structure is 
not biased to the β2AR structure. This is supported by low Rwork and Rfree values 
(Supplementary Table 2). All refinements were performed with REFMAC5 8 and 
autoBUSTER 9 followed by manual examination and rebuilding of the refined coordinates in 
the program Coot 10. The non-lysozyme portion contains higher B-factors (116Å2) due to 
fewer contacts as compared to T4 lysozyme (36 Å2). Calculation of the surface area buried by 
crystal contacts also explains this. For the non-lysozyme portion, only 8% (1,225 Å2) of 
15,689 Å2 solvent accessible surface area is buried by crystal contacts. In contrast, for the T4 
lysozyme portion, 32% (2,733 Å2) of the solvent accessible area (8,648 Å2) is buried by 
crystal interactions. Supplementary Figure 4 also shows there are strong interactions between 
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T4 lysozyme domains, but relatively fewer between non-lysozyme domains throughout the 
crystal packing.  Although the average B-factor of the non-lysozyme domain is high as 
compared to T4 lysozyme, as shown in the supplementary Figures 3 and 4, electron densities 
were clear for unambiguous model building. The H1R 8 N-terminal residues (Thr20-Leu27), 2 
C-terminal residues (Arg486-Ser487), and 7 residues (Phe168-Val174) in the second 
extracellular loop (ECL2) are not included in the structure as they did not have interpretable 
densities.  
Strong and spherical electron densities (about 4 sigma) were found in the 
anion-binding region in the Fo-Fc omit map. We excluded the presence of a water molecule 
in this region due to strong residual positive Fo-Fc densities when we modeled it as a water 
molecule. The coordination geometry in the highly electropositive environment surrounded 
by His4507.35, Lys179 and Lys1915.39 implied that either a phosphate or sulfate ion could be 
modeled. Since ammonium phosphate was added to our crystallization buffer, we modeled it 
as a phosphate ion. The average B-factors of the phosphate ion and the interacting atoms are 
177 Å2 and154 Å2, respectively. 
  
Ligand binding assays 
For the saturation binding experiment, yeast membrane suspensions containing 
H1R-fl-GFP (20 µg) or H1R-T4L-GFP (5 µg) were incubated with increasing concentrations 
of [3H] pyrilamine (from 0.15 to 40 nM) in a total assay volume of 200 µl for 1 h at 25 ºC. In 
order to investigate effect of phosphate on the ligand binding, assays were performed in PBS 
buffer pH 7.4 (138 mM NaCl, 8.1 mM Na2HPO4, 27 mM KCl, 1.8 mM KH2PO4) or in the 
HEPES buffer containing 20 mM HEPES pH 7.5 and 150 mM NaCl. Nonspecific binding 
was determined in the presence of 1000-times excess unlabeled pyrilamine. Membranes were 
trapped on Whatman GF/B filters pre-soaked in 0.3% polyethylenimine, and unbound 
radioligands were washed with 9 ml of the PBS or the HEPES buffers. The retained 
radioactivity was measured on an LCS-5100 liquid scintillation counter (ALOKA) in a 
Clearzol I scintillation liquid (Nakarai, Japan). Data were analyzed by non-linear curve-fitting 
with a rectangular hyperbola function using the Prism 4.0 software (GraphPad) to determine 
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dissociation constant (Kd).  
For competition binding assays, yeast membrane suspensions containing 
H1R-fl-GFP or H1R-T4L-GFP were incubated with 4 nM or 20 nM [3H]pyrilamine in the PBS 
buffer or the HEPES buffer in the presence of 10 nM to 100 mM histamine hydrochloride or 
0.001 nM to 1 µM doxepin, or 0.01 nM to 10 µM cetirizine, pyrilamine, olopatadine and 
fexofenadine. Data were analyzed by non-linear curve fitting with a sigmoidal function using 
the Prism 4.0 to determine the half maximal inhibitory concentrations (IC50). All data shown 
calculated based on more than three independent experiments. Inhibition constant Ki was 
calculated based on the equation Ki = IC50/(1+L/Kd), where L is the concentration of 
[3H]pyrilamine with the dissociation constant Kd. 
 
Thermal stability assay 
N-[4-(7-diethylamino-4-methyl-3-coumarinyl)phenyl]maleimide (CPM) dye was 
purchased from Invitrogen and dissolved in DMSO (Sigma) at 4 mg/ml as the stock solution 
for future use. The stock solution was kept at −80°C and was diluted 1:40 in dye dilution 
solution (10 mM buffer, 500 mM NaCl, 10% glycerol, 0.025% DDM and 0.005% CHS) 
before use. The thermal denaturation assay was performed with total volume of 200 µl sample 
in a quartz fluorometer cuvette (Starna Cells, Inc., Atascadero, CA). H1R (4 µg) was diluted 
in the appropriate buffer solution to a final volume of 200 µl.  Five micro litter of the diluted 
dye was added to the protein solution and it was incubated for 30 min at 4°C. The mixed 
solution was transferred to the cuvette and the data were collected by a Cary Eclipse 
spectrofluorometer (Varian, USA) with a temperature ramping rate at 1°C/min. The excitation 
wavelength was 387 nm and the emission wavelength was 463 nm. All assays were 
performed over a temperature range starting from 20°C and 80°C. The stability data were 
processed with GraphPad Prism program (GraphPadPrism, Graphpad Sofware, San Diego, 
CA, USA). In order to determine the melting temperature (Tm), a Bolzmann sigmoidal 
equation was used to fit to the data.  
 
Flexible Ligand-Receptor Docking 
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Docking of ligands was performed using all-atom flexible receptor docking 
algorithm in ICM-Pro molecular modeling package11 as described previously 12-13. The initial 
H1R receptor model was generated in ICM by building hydrogen atoms for the crystal 
structure of H1R. Internal coordinate (torsion) movements were allowed in the side chains of 
the binding pocket, defined as residues within 8Å distance of doxepin in the H1R-doxepin 
complex. Other side chains and backbone of the protein were kept as in the crystal structure. 
An initial conformation for each of the ligands was generated by Cartesian optimization of the 
ligand model in MMFF force field.  Docking was performed by placing the ligand in a 
random position within 5Å from the binding pocket and global optimization of the complex 
conformational energy. The global energy of the complex was calculated as a sum of van der 
Waals, electrostatic, hydrogen-bonding and torsion stress terms. Stochastic global energy 
optimization of the complex was performed using the ICM Monte Carlo (MC) procedure with 
minimization14. To facilitate side chain rotamer switches in flexible H1R models, the first 106 
steps of the MC procedure used ‘‘soft’’ vdW potentials and high MC temperature, followed 
by another 106 steps with ‘‘exact’’ vdW method and gradually decreasing temperature.  A 
harmonic ‘‘distance restraint’’ has been applied between amino group of the ligand and 
carboxyl of Asp107 side chain in the initial 106 steps to facilitate formation of the known salt 
bridge interaction between these two groups. At least 10 independent runs of the docking 
procedure were performed for each H1R-ligand. The docking results were considered 
‘‘consistent’’ when at least 80% of the individual runs resulted in conformations clustered 
within a RMSD of <0.5 Å to the overall best energy pose of the ligand. 
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